In summary, our work sets the basis for the use of dinaciclib in chemotherapy-resistant SCLC and a rationale to introduce specific CDK9 inhibitors with comparable anti-tumour efficacy and safety profile. The gene discussed is CDK9; the disease is neoplasm.